Pharmaceuticals

Lynx Analytics Unveils LynxKite 2000:MM - The Next Generation of GPU-Optimized Graph AI

LOS GATOS, Calif., March 19, 2025 /PRNewswire/ -- Lynx Analytics, a member of theNVIDIA Inception program for startups, today announced the launch ofLynxKite 2000:MM , the most advanced version of its Graph AI platf...

2025-03-19 21:00 1654

"Miracle Doctor" Dr. Wei-Hua Chen: Role of Oligo Fucoidan in Cancer Care

LOS ANGELES, March 19, 2025 /PRNewswire/ -- Dr. Wei-Hua Chen, a renowned 70-year-old cardiologist and the director of Hongxin Clinic (Taichung,Taiwan), has been awarded the "28th Fervent Global Love of Lives Award 2025" by the Chou Ta-Kuan Cultural and Educational Foundation. First diagnosed with...

2025-03-19 20:00 1390

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China

SAN FRANCISCO and SUZHOU, China, March 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2025-03-19 09:20 2216

CARsgen Announced 2024 Annual Results

SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results. Business Highlights * Zevor-cel was approved by China's National Medical Products Administra...

2025-03-19 08:15 3376

Bloomage Passes GMP Audit by South Korea's MFDS, Strengthening its Global Quality Assurance

PARSIPPANY, NJ., March 18, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has successfully passed the GMP on-site inspection bySouth Korea's Ministry of Food and Drug Safety (MFDS) with no observations of non-compliance. This certifica...

2025-03-18 21:00 2040

A chronographic analysis of MSC's rollercoasting journey

TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking discussions about the historical development of me...

2025-03-18 20:00 1997

Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension

This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries. TAIPEI, March 18, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipl...

2025-03-18 16:00 1666

A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™

SINGAPORE, March 18, 2025 /PRNewswire/ -- HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in the United States. This marks a significant milest...

2025-03-18 11:00 1674

Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D Projects for NTDs With Partners Including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories

TOKYO, March 18, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.7 billion ( USD 11.4 million1) in five projects for the development of schistosomiasis diagnostics and drugs for neglected tropical diseases (NTDs).2  ...

2025-03-18 10:42 1705

Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC

SUZHOU, China, March 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Breakthrough Therapy Designation by the ...

2025-03-18 09:47 2223

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit fo...

2025-03-18 06:52 2678

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

* Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design,...

2025-03-17 21:00 1824

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

SHANGHAI, March 17, 2025 /PRNewswire/ -- Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for se...

2025-03-17 19:00 4120

Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies

HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund an...

2025-03-17 18:00 2022

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasop...

2025-03-17 11:49 1985

HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease

* Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). * Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and accessibility. * Phase 3 study to confirm the potential...

2025-03-17 07:59 2347

Florbetaben (18F) Injection (Neuraceq®) Set to Launch at St. Teresa's Hospital in Hong Kong in March 2025

Innovative Imaging Solution to Enhance Alzheimer's Disease Diagnosis and Patient Care in the Region BOSTON, March 14, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be available in ...

2025-03-14 21:00 3811

Azurity Pharmaceuticals Completes Acquisition of Covis Pharma

WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals  ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.      This strategic ...

2025-03-14 20:52 2808

China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...

2025-03-14 16:35 3990

Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma

HONG KONG, March 14, 2025 /PRNewswire/ -- Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Kerry Pharma's extensive logistics (fourth-party logistics, 4PL) distribution capabilities, this collaborat...

2025-03-14 15:27 3254
1 ... 50515253545556 ... 337